【作者】 闫秀峰；

【导师】 栗德林；

【作者基本信息】 黑龙江中医药大学 ， 中医内科学， 2002， 博士

【摘要】 本文在系统整理糖尿病(DM)合并冠心病(CHD)中西医治疗进展的基础上，运用栗德林教授提出的有关本病的新发病理论和拟定的益气养阴、活血化痰的治疗本病大法，以创立的糖冠康软胶囊治疗并对其作用机理进行了探讨。研究结果表明：1、糖冠康治疗本病总有效率达91.18％，与对照组比较有显著性差异(P＜0.05)；2、糖冠康具有显著改善本病患者的临床表现的作用，并具有降糖、调脂、降粘、降纤、改善心功、抗心肌缺血、抗心绞痛、改善胰岛B细胞功能、改善胰岛素抵抗(IR)等综合功效；3、糖冠康对患者血浆sICAM-1、sVCAM-1、IGF-1和VEGF水平有很好的改善作用，并可能是通过其组成药物的现代药理学功能，通过抑制sICAM-1、sVCAM-1水平来抑制血管内皮细胞的炎症反应，进而防止动脉粥样硬化的发生和发展、防止粥样硬化斑块破裂和稳定冠心病病情，以及通过促进IGF-1和VEGF的表达来更好地降糖、调脂、改善IR、改善心功和促进缺血心肌侧支循环建立、防止心梗、改善患者预后等作用来实现治疗效应的。更多还原

【Abstract】 To observe the clinical effects of TangGuanKang in treating CHD complicated by DM (type 2) and the latent pharmacological mechanism of its therapeutic effects, We have established systemic clinical studies.The results show that: (1) the total therapeutic effective rate of TangGuanKang is 91.18%,significantly better than that of the control group (P<0.05); (2)TangGuanKang can significantly improve the patients’ clinical symptoms and experimental data, including FBG, P2hBG, HbA1c,blood lipid , blood viscosity, left ventricular function, TIB, angina pectoris, insulin resistance and the function of islet B cells of the Pancreas; (3)TangGuanKang can significantly improve the level of sICAM-l,sVCAM-l,IGF-l and VEGF in plasma; ﹖he mechanism of TangGuanKang in treating this disease may be through the modern pharmacological functions of its ingredients; through descending the level of sICAM-1 and sVCAM-1 in plasma which can get AS formation and the inflammation of vascular endothelium inhibited and prevent the clots of AS from rupturing; and through promoting the expression of IGF-1 and VEGF to lower blood glucose, regulate blood lipid, improve IR and left ventricular function, promote collateral circulation in ischemic cardiac muscles, avoid AMI and improve the prognosis of this disease.更多还原